Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gefitinib.

Christine R Culy1, Diana Faulds

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz

Drugs
|October 17, 2002
PubMed
Summary
This summary is machine-generated.

Gefitinib, an epidermal growth factor receptor inhibitor, demonstrated efficacy in non-small cell lung cancer (NSCLC) patients. It showed objective responses and symptom improvement, with manageable side effects like rash and diarrhea.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum to: Maclobemide.

Drugs·2017
Same author

Erratum to: Moclobemide.

Drugs·2017
Same author

Erratum to: Cyclosporin: A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use in Immunoregulatory Disorders.

Drugs·2017
Same author

Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery.

Drugs·2004
Same author

Latanoprost : an update of its use in glaucoma and ocular hypertension.

Drugs & aging·2003
Same author

Spotlight on etanercept in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2003
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Epidermal growth factor receptor (EGFR) signaling pathways are crucial for cancer cell proliferation and survival.
  • Targeting EGFR tyrosine kinase offers a potential therapeutic strategy for cancer treatment.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of gefitinib, an orally active selective EGFR tyrosine kinase inhibitor, in patients with advanced non-small cell lung cancer (NSCLC).

Main Methods:

  • Gefitinib's effects on NSCLC cell lines and xenografts were assessed for cellular proliferation and tumor growth inhibition.
  • Clinical trials evaluated gefitinib's oral bioavailability, pharmacokinetic profile (CYP450 3A4 pathway), and efficacy in NSCLC patients who had failed prior chemotherapy.
  • Objective response rates and disease-related symptom improvements were measured in double-blind trials.

Related Experiment Videos

Main Results:

  • Gefitinib demonstrated dose-dependent inhibition of proliferation and tumor growth in preclinical models.
  • In advanced NSCLC patients, gefitinib (250-500 mg/day) achieved objective response rates of approximately 19% and 11.8-8.8% in different trials.
  • Around 40% of patients experienced improvement in disease-related symptoms, and the drug was generally well tolerated with common side effects including mild rash and diarrhea.

Conclusions:

  • Gefitinib is an orally bioavailable EGFR tyrosine kinase inhibitor with demonstrated activity in advanced NSCLC.
  • The drug shows potential as a treatment option for NSCLC patients, particularly those who have progressed on prior chemotherapy.
  • Gefitinib exhibits a generally favorable safety profile, with manageable adverse events.